Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 10, 2014, Pages 1861-1869

  Lewandowski, Robert J ^a   Memon, Khairuddin ^a   Mulcahy, Mary F ^b   Hickey, Ryan ^a   Marshall, Karen ^a,b   Williams, Melissa ^a,b   Salzig, Krystina ^a,b   Gates, Vanessa L ^a   Atassi, Bassel ^a   Vouche, Michael ^a   Atassi, Rohi ^a   Desai, Kush ^a   Hohlastos, Elias ^a   Sato, Kent ^a   Habib, Ali ^a   Kircher, Sheetal ^b   Newman, Steven B ^b   Nimeiri, Halla ^b   Benson, Al B ^b   Salem, Riad ^a,b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Colorectal metastases; Radioembolization; SIRT; Survival; Yttrium 90

Indexed keywords

RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ADVERSE EFFECTS; AGED; ARTIFICIAL EMBOLISM; CARCINOMA; CHEMORADIOTHERAPY; COLORECTAL TUMOR; FEMALE; HUMAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; SECONDARY; SURVIVAL;

AGED; CARCINOMA; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; YTTRIUM RADIOISOTOPES;

EID: 84930735746     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2799-2     Document Type: Article

References (42)

1. Sasson AR, Sigurdson ER. Surgical treatment of liver metastases. Semin Oncol. 2002;29:107–18.
2. Macdonald J. Adjuvant therapy of colon cancer. CA Cancer J Clin. 1999;49:202–19.
3. Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med. 2005;56:139–56. doi:10.1146/annurev.med.56.082103.104630.
4. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575–80. doi:10.1200/JCO.2007.11.0833.
5. Albert M, Kiefer MV, Sun W, Haller D, Fraker DL, Tuite CM, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer. 2011;117:343–52. doi:10.1002/cncr.25387.
6. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson 3rd AB, Blanke CD, Diasio RB, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12:38–50. doi:10.1634/theoncologist.12-1-38.
7. Mulcahy MF, Lewandowski RJ, Ibrahim SM, Sato KT, Ryu RK, Atassi B, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009;115:1849–58.
8. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44. doi:10.1200/JCO.2006.09.6305.
9. Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007;7:91. doi:10.1186/1471-2407-7-91.
10. Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981;141:586–9.
11. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg. 1984;199:502–8.
12. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497–507 e2. doi:10.1053/j.gastro.2010.10.049.
13. Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22:265–78. doi:10.1016/j.jvir.2010.10.029.
14. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52–64. doi:10.1053/j.gastro.2009.09.006.
15. Bangash AK, Atassi B, Kaklamani V, Rhee TK, Yu M, Lewandowski RJ, et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol. 2007;18:621–8.
16. Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271–9.
17. Jakobs TF, Hoffmann RT, Dehm K, Trumm C, Stemmler HJ, Tatsch K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008;19:1187–95. doi:10.1016/j.jvir.2008.05.013.
18. Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman Jr DE, Loehr SP, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412–25.
19. Gates VL, Marshall KG, Salzig K, Williams M, Lewandowski RJ, Salem R. Outpatient single-session yttrium-90 glass microsphere radioembolization. J Vasc Interv Radiol. 2014;25:266–70. doi:10.1016/j.jvir.2013.11.005.
20. Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek Jr AA, Kulik L, et al. Radioembolization with (90)y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571–92.
21. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251–78.
22. Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol. 2006;17:1425–39.
23. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol. 2006;17:1571–93.
24. Salem R, Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Ibrahim S, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol. 2007;10:12–29.
25. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13:S223–9.
26. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293–8.
27. Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40:583–92.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
29. Gyorffy B, Gyorffy A. Tulassay Z [The problem of multiple testing and solutions for genome-wide studies]. Orv Hetil. 2005;146:559–63.
30. Cleophas TJ, Zwinderman AH. Clinical trials are often false positive: a review of simple methods to control this problem. Curr Clin Pharmacol. 2006;1:1–4.
31. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12. doi:10.1016/S0140-6736(12)61900-X.
32. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040–8.
33. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007;110:980–8. doi:10.1002/cncr.22915.
34. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28:1254–61. doi:10.1200/JCO.2009.24.6116.
35. Benson 3rd AB, Geschwind JF, Mulcahy MF, Rilling W, Siskin G, Wiseman G, et al. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer. 2013;49:3122–30. doi:10.1016/j.ejca.2013.05.012.
36. Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25:1099–106.
37. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28:3687–94. doi:10.1200/JCO.2010.28.5643.
38. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30:969–77.
39. Ackerman NB, Lien WM, Silverman NA. The blood supply of experimental liver metastases. 3. The effects of acute ligation of the hepatic artery or portal vein. Surgery. 1972;71:636–41.
40. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13–23.
41. Evans KA, Richardson MG, Pavlakis N, Morris DL, Liauw W, Bester L. Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres. J Vasc Interv Radiol. 2010;21:1521–6. doi:10.1016/j.jvir.2010.06.018.
42. Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN, et al. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer. 2014;13:27–36. doi:10.1016/j.clcc.2013.11.010.